Trial Outcomes & Findings for A Clinical Trial to Assess the Safety and the Anti-caries Efficacy of COL 101 (Arginine) Non-fluoride Dentifrices in Comparison With 0.24% Sodium Fluoride (1100 Ppm F) Dentifrice Control in 10 to 14-year-old Children (NCT NCT04750902)
NCT ID: NCT04750902
Last Updated: 2026-07-21
Results Overview
The Decayed Missing or Filled Surfaces (DMFS) score is a measure of the extent of dental caries for a subject, defined as the number of scorable tooth surfaces among the up to 128 examined surfaces in the subject's mouth that were determined by the examiner to be decayed, missing, or filled. This score can range between 0 and 128, with higher values indicating a greater level of disease (i.e., worse condition). The Incremental DMFS is defined as the change in DMFS score between two examinations performed at specified time points, calculated by subtraction.
COMPLETED
PHASE2
2025 participants
Between the Baseline and the Month 12 visits
2026-07-21
Participant Flow
Participant milestones
| Measure |
0.24% Sodium Fluoride Dentifrice
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
1.5% Arginine Dentifrice
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
500
|
510
|
506
|
509
|
|
Overall Study
COMPLETED
|
387
|
389
|
392
|
409
|
|
Overall Study
NOT COMPLETED
|
113
|
121
|
114
|
100
|
Reasons for withdrawal
| Measure |
0.24% Sodium Fluoride Dentifrice
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
1.5% Arginine Dentifrice
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Overall Study
Adverse Event
|
0
|
0
|
1
|
0
|
|
Overall Study
Physician Decision
|
3
|
6
|
0
|
3
|
|
Overall Study
Protocol Violation
|
40
|
46
|
36
|
34
|
|
Overall Study
Sponsor request
|
3
|
0
|
0
|
1
|
|
Overall Study
Withdrawal by Subject
|
14
|
15
|
22
|
7
|
|
Overall Study
Other
|
53
|
54
|
55
|
55
|
Baseline Characteristics
A Clinical Trial to Assess the Safety and the Anti-caries Efficacy of COL 101 (Arginine) Non-fluoride Dentifrices in Comparison With 0.24% Sodium Fluoride (1100 Ppm F) Dentifrice Control in 10 to 14-year-old Children
Baseline characteristics by cohort
| Measure |
0.24% Sodium Fluoride Dentifrice
n=500 Participants
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
1.5% Arginine Dentifrice
n=510 Participants
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=506 Participants
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=509 Participants
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
Total
n=2025 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|
|
Age, Continuous
|
12.2 Years
STANDARD_DEVIATION 1.35 • n=9 Participants
|
12.1 Years
STANDARD_DEVIATION 1.40 • n=27 Participants
|
12.2 Years
STANDARD_DEVIATION 1.40 • n=267 Participants
|
12.1 Years
STANDARD_DEVIATION 1.37 • n=265 Participants
|
12.1 Years
STANDARD_DEVIATION 1.38 • n=568 Participants
|
|
Sex/Gender, Customized
Unknown gender
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
1 Participants
n=265 Participants
|
1 Participants
n=568 Participants
|
|
Sex/Gender, Customized
Male
|
236 Participants
n=9 Participants
|
256 Participants
n=27 Participants
|
234 Participants
n=267 Participants
|
256 Participants
n=265 Participants
|
982 Participants
n=568 Participants
|
|
Sex/Gender, Customized
Female
|
264 Participants
n=9 Participants
|
254 Participants
n=27 Participants
|
272 Participants
n=267 Participants
|
252 Participants
n=265 Participants
|
1042 Participants
n=568 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
332 Participants
n=9 Participants
|
323 Participants
n=27 Participants
|
325 Participants
n=267 Participants
|
324 Participants
n=265 Participants
|
1304 Participants
n=568 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
148 Participants
n=9 Participants
|
171 Participants
n=27 Participants
|
165 Participants
n=267 Participants
|
168 Participants
n=265 Participants
|
652 Participants
n=568 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
20 Participants
n=9 Participants
|
16 Participants
n=27 Participants
|
16 Participants
n=267 Participants
|
17 Participants
n=265 Participants
|
69 Participants
n=568 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
4 Participants
n=9 Participants
|
4 Participants
n=27 Participants
|
5 Participants
n=267 Participants
|
1 Participants
n=265 Participants
|
14 Participants
n=568 Participants
|
|
Race (NIH/OMB)
Asian
|
16 Participants
n=9 Participants
|
17 Participants
n=27 Participants
|
20 Participants
n=267 Participants
|
19 Participants
n=265 Participants
|
72 Participants
n=568 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
2 Participants
n=9 Participants
|
2 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
1 Participants
n=265 Participants
|
5 Participants
n=568 Participants
|
|
Race (NIH/OMB)
Black or African American
|
130 Participants
n=9 Participants
|
155 Participants
n=27 Participants
|
140 Participants
n=267 Participants
|
161 Participants
n=265 Participants
|
586 Participants
n=568 Participants
|
|
Race (NIH/OMB)
White
|
305 Participants
n=9 Participants
|
290 Participants
n=27 Participants
|
300 Participants
n=267 Participants
|
285 Participants
n=265 Participants
|
1180 Participants
n=568 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=267 Participants
|
0 Participants
n=265 Participants
|
0 Participants
n=568 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
43 Participants
n=9 Participants
|
42 Participants
n=27 Participants
|
41 Participants
n=267 Participants
|
42 Participants
n=265 Participants
|
168 Participants
n=568 Participants
|
PRIMARY outcome
Timeframe: Between the Baseline and the Month 12 visitsPopulation: The primary efficacy analysis was based on the Per-Protocol population, which consisted of those subjects in the Intent-to-Treat population who completed all study examinations, and who experienced no serious protocol violations.
The Decayed Missing or Filled Surfaces (DMFS) score is a measure of the extent of dental caries for a subject, defined as the number of scorable tooth surfaces among the up to 128 examined surfaces in the subject's mouth that were determined by the examiner to be decayed, missing, or filled. This score can range between 0 and 128, with higher values indicating a greater level of disease (i.e., worse condition). The Incremental DMFS is defined as the change in DMFS score between two examinations performed at specified time points, calculated by subtraction.
Outcome measures
| Measure |
1.5% Arginine Dentifrice
n=388 Participants
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=391 Participants
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=407 Participants
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
0.24% Sodium Fluoride Dentifrice
n=386 Participants
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Incremental Subject-wise Decayed Missing or Filled Surfaces (DMFS) Score Between the Baseline and the Month 12 Visits
|
1.43 units on a scale
Standard Deviation 2.92
|
1.54 units on a scale
Standard Deviation 3.07
|
1.73 units on a scale
Standard Deviation 3.97
|
1.18 units on a scale
Standard Deviation 2.57
|
SECONDARY outcome
Timeframe: Between the Baseline and the Month 6 visitsPopulation: Analysis was performed on Intent-to-Treat population, which consisted of all subjects who were randomized and dispensed study treatment. Subjects with data available at the required visits are considered for analysis.
The Decayed Missing or Filled Surfaces (DMFS) score is a measure of the extent of dental caries for a subject, defined as the number of scorable tooth surfaces among the up to 128 examined surfaces in the subject's mouth that were determined by the examiner to be decayed, missing, or filled. This score can range between 0 and 128, with higher values indicating a greater level of disease (i.e., worse condition). The Incremental DMFS is defined as the change in DMFS score between two examinations performed at specified time points, calculated by subtraction.
Outcome measures
| Measure |
1.5% Arginine Dentifrice
n=418 Participants
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=421 Participants
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=430 Participants
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
0.24% Sodium Fluoride Dentifrice
n=411 Participants
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Incremental Subject-wise Decayed Missing or Filled Surfaces (DMFS) Score Between the Baseline and the Month 6 Visits
|
0.70 units on a scale
Standard Deviation 2.01
|
0.88 units on a scale
Standard Deviation 2.55
|
0.92 units on a scale
Standard Deviation 2.72
|
0.71 units on a scale
Standard Deviation 2.05
|
SECONDARY outcome
Timeframe: Between the Month 6 and the Month 12 visitsPopulation: Analysis was performed on Intent-to-Treat population, which consisted of all subjects who were randomized and dispensed study treatment. Subjects with data available at the required visits are considered for analysis.
The Decayed Missing or Filled Surfaces (DMFS) score is a measure of the extent of dental caries for a subject, defined as the number of scorable tooth surfaces among the up to 128 examined surfaces in the subject's mouth that were determined by the examiner to be decayed, missing, or filled. This score can range between 0 and 128, with higher values indicating a greater level of disease (i.e., worse condition). The Incremental DMFS is defined as the change in DMFS score between two examinations performed at specified time points, calculated by subtraction.
Outcome measures
| Measure |
1.5% Arginine Dentifrice
n=389 Participants
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=392 Participants
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=409 Participants
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
0.24% Sodium Fluoride Dentifrice
n=388 Participants
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Incremental Subject-wise Decayed Missing or Filled Surfaces (DMFS) Score Between the Month 6 and Month 12 Visits
|
0.72 units on a scale
Standard Deviation 2.18
|
0.72 units on a scale
Standard Deviation 2.08
|
0.81 units on a scale
Standard Deviation 2.66
|
0.51 units on a scale
Standard Deviation 1.63
|
SECONDARY outcome
Timeframe: Between the Baseline and the Month 6 visitsPopulation: Analysis was performed on Intent-to-Treat population, which consisted of all subjects who were randomized and dispensed study treatment. Subjects with data available at the required visits are considered for analysis.
The Decayed Missing or Filled Teeth (DMFT) score is a measure of the extent of dental caries for a subject, defined as the number of the up to 28 examined teeth in the subject's mouth on which the examiner determined at least one surface to be decayed, missing, or filled. This score can range between 0 and 28, with higher values indicating a greater level of disease (i.e., worse condition). The Incremental DMFT is defined as the change in DMFT score between two examinations performed at specified time points, calculated by subtraction.
Outcome measures
| Measure |
1.5% Arginine Dentifrice
n=418 Participants
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=421 Participants
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=430 Participants
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
0.24% Sodium Fluoride Dentifrice
n=411 Participants
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Incremental Subject-wise Decayed Missing or Filled Teeth (DMFT) Score Between the Baseline and the Month 6 Visits
|
0.38 units on a scale
Standard Deviation 1.06
|
0.47 units on a scale
Standard Deviation 1.41
|
0.45 units on a scale
Standard Deviation 1.31
|
0.32 units on a scale
Standard Deviation 1.12
|
SECONDARY outcome
Timeframe: Between the Baseline and the Month 12 visitsPopulation: Analysis was performed on Intent-to-Treat population, which consisted of all subjects who were randomized and dispensed study treatment. Subjects with data available at the required visits are considered for analysis.
The Decayed Missing or Filled Teeth (DMFT) score is a measure of the extent of dental caries for a subject, defined as the number of the up to 28 examined teeth in the subject's mouth on which the examiner determined at least one surface to be decayed, missing, or filled. This score can range between 0 and 28, with higher values indicating a greater level of disease (i.e., worse condition). The Incremental DMFT is defined as the change in DMFT score between two examinations performed at specified time points calculated by subtraction.
Outcome measures
| Measure |
1.5% Arginine Dentifrice
n=389 Participants
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=393 Participants
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=409 Participants
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
0.24% Sodium Fluoride Dentifrice
n=388 Participants
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Incremental Subject-wise Decayed Missing or Filled Teeth (DMFT) Score Between the Baseline and the Month 12 Visits
|
0.73 units on a scale
Standard Deviation 1.49
|
0.79 units on a scale
Standard Deviation 1.69
|
0.86 units on a scale
Standard Deviation 1.81
|
0.64 units on a scale
Standard Deviation 1.45
|
SECONDARY outcome
Timeframe: Between the Month 6 and the Month 12 visitsPopulation: Analysis was performed on Intent-to-Treat population, which consisted of all subjects who were randomized and dispensed study treatment. Subjects with data available at the required visits are considered for analysis.
The Decayed Missing or Filled Teeth (DMFT) score is a measure of the extent of dental caries for a subject, defined as the number of the up to 28 examined teeth in the subject's mouth on which the examiner determined at least one surface to be decayed, missing, or filled. This score can range between 0 and 28, with higher values indicating a greater level of disease (i.e., worse condition). The Incremental DMFT is defined as the change in DMFT score between two examinations performed at specified time points, calculated by subtraction.
Outcome measures
| Measure |
1.5% Arginine Dentifrice
n=389 Participants
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=392 Participants
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=409 Participants
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
0.24% Sodium Fluoride Dentifrice
n=388 Participants
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Incremental Subject-wise Decayed Missing or Filled Teeth (DMFT) Score Between the Month 6 and the Month 12 Visits
|
0.37 units on a scale
Standard Deviation 1.20
|
0.32 units on a scale
Standard Deviation 0.98
|
0.41 units on a scale
Standard Deviation 1.19
|
0.31 units on a scale
Standard Deviation 0.96
|
SECONDARY outcome
Timeframe: Between the Baseline and the Month 6 visitsPopulation: This parameter was analyzed in the Intent-to-Treat Population, which consisted of all subjects who were randomized and dispensed study treatment. Subjects with data available at the required visits are considered for analysis.
The ICDAS caries severity score is a parameter that reports the level of dental caries on each tooth surface using a 7-point ordinal scale ranging from 0 to 6, where higher scores are worse. When considering the time frame between two specified examinations, a clinically significant score progression is defined as a worsening from a score of 0 to a score of 2 or higher; from a score of 1 or 2 to a score of 3 or higher; or from a score of 3 or 4 to a score of 5 or 6. Surfaces with scores between 0 and 4 at the earlier examination are defined as being at risk for caries severity progression. For each subject, the number of at-risk tooth surfaces was recorded, as well as the number of those at-risk surfaces that presented a clinically significant caries severity progression between the two examinations. For each treatment group, the mean of the subject-wise percentages of at-risk surfaces exhibiting a clinically significant caries progression was calculated.
Outcome measures
| Measure |
1.5% Arginine Dentifrice
n=418 Participants
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=421 Participants
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=430 Participants
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
0.24% Sodium Fluoride Dentifrice
n=411 Participants
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Subject-wise Tallies of Clinically Significant International Caries Detection and Assessment System (ICDAS) Severity Score Progressions Between the Baseline and the Month 6 Visits
|
2.57 Percentage of tooth surfaces
Standard Deviation 3.58
|
2.91 Percentage of tooth surfaces
Standard Deviation 5.57
|
2.24 Percentage of tooth surfaces
Standard Deviation 3.11
|
2.37 Percentage of tooth surfaces
Standard Deviation 3.37
|
SECONDARY outcome
Timeframe: Between the Baseline and the Month 12 visitsPopulation: This parameter was analyzed in the Intent-to-Treat Population, which consisted of all subjects who were randomized and dispensed study treatment. Subjects with data available at the required visits are considered for analysis.
The ICDAS caries severity score is a parameter that reports the level of dental caries on each tooth surface using a 7-point ordinal scale ranging from 0 to 6, where higher scores are worse. When considering the time frame between two specified examinations, a clinically significant score progression is defined as a worsening from a score of 0 to a score of 2 or higher; from a score of 1 or 2 to a score of 3 or higher; or from a score of 3 or 4 to a score of 5 or 6. Surfaces with scores between 0 and 4 at the earlier examination are defined as being at risk for caries severity progression. For each subject, the number of at-risk tooth surfaces was recorded, as well as the number of those at-risk surfaces that presented a clinically significant caries severity progression between the two examinations. For each treatment group, the mean of the subject-wise percentages of at-risk surfaces exhibiting a clinically significant caries progression was calculated.
Outcome measures
| Measure |
1.5% Arginine Dentifrice
n=389 Participants
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=393 Participants
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=409 Participants
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
0.24% Sodium Fluoride Dentifrice
n=388 Participants
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Subject-wise Tallies of Clinically Significant International Caries Detection and Assessment System (ICDAS) Severity Score Progressions Between the Baseline and the Month 12 Visits
|
3.07 Percentage of tooth surfaces
Standard Deviation 3.85
|
3.71 Percentage of tooth surfaces
Standard Deviation 5.81
|
3.07 Percentage of tooth surfaces
Standard Deviation 3.98
|
2.62 Percentage of tooth surfaces
Standard Deviation 3.59
|
SECONDARY outcome
Timeframe: Between the Month 6 and the Month 12 visitsPopulation: This parameter was analyzed in the Intent-to-Treat Population, which consisted of all subjects who were randomized and dispensed study treatment. Subjects with data available at the required visits are considered for analysis.
The ICDAS caries severity score is a parameter that reports the level of dental caries on each tooth surface using a 7-point ordinal scale ranging from 0 to 6, where higher scores are worse. When considering the time frame between two specified examinations, a clinically significant score progression is defined as a worsening from a score of 0 to a score of 2 or higher; from a score of 1 or 2 to a score of 3 or higher; or from a score of 3 or 4 to a score of 5 or 6. Surfaces with scores between 0 and 4 at the earlier examination are defined as being at risk for caries severity progression. For each subject, the number of at-risk tooth surfaces was recorded, as well as the number of those at-risk surfaces that presented a clinically significant caries severity progression between the two examinations. For each treatment group, the mean of the subject-wise percentages of at-risk surfaces exhibiting a clinically significant caries progression was calculated.
Outcome measures
| Measure |
1.5% Arginine Dentifrice
n=389 Participants
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=392 Participants
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=409 Participants
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
0.24% Sodium Fluoride Dentifrice
n=388 Participants
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Subject-wise Tallies of Clinically Significant International Caries Detection and Assessment System (ICDAS) Severity Score Progressions Between the Month 6 and the Month 12 Visits
|
2.57 Percentage of tooth surfaces
Standard Deviation 3.90
|
2.72 Percentage of tooth surfaces
Standard Deviation 3.88
|
2.38 Percentage of tooth surfaces
Standard Deviation 3.48
|
1.93 Percentage of tooth surfaces
Standard Deviation 2.91
|
SECONDARY outcome
Timeframe: Between the Baseline and the Month 6 visitsPopulation: This parameter was analyzed in the Intent-to-Treat Population, which consisted of all subjects who were randomized and dispensed study treatment. Subjects with data available at the required visits are considered for analysis.
The ICDAS caries severity score is a parameter that reports the level of dental caries on each tooth surface using a 7-point ordinal scale ranging from 0 to 6, where higher scores are worse. When considering the time frame between two specified examinations, a clinically significant score severity score regression on a tooth surface is defined as an improvement from a score of 2 or higher to a score of 0 or 1. Tooth surfaces for which the earlier score was between 2 and 6 are defined as being at risk for caries severity regression. For each subject, the number of at-risk tooth surfaces was recorded, as well as the number of those at-risk surfaces that presented a clinically significant caries severity regression between the two examinations. For each treatment group, the mean of the subject-wise percentages of at-risk surfaces exhibiting a clinically significant caries regression was calculated.
Outcome measures
| Measure |
1.5% Arginine Dentifrice
n=418 Participants
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=421 Participants
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=430 Participants
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
0.24% Sodium Fluoride Dentifrice
n=411 Participants
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Subject-wise Tallies of Clinically Significant International Caries Detection and Assessment System (ICDAS) Caries Severity Score Regressions Between the Baseline and the Month 6 Visits
|
27.77 Percentage of tooth surfaces
Standard Deviation 27.84
|
28.46 Percentage of tooth surfaces
Standard Deviation 27.56
|
28.38 Percentage of tooth surfaces
Standard Deviation 27.01
|
28.84 Percentage of tooth surfaces
Standard Deviation 28.82
|
SECONDARY outcome
Timeframe: Between the Baseline and the Month 12 visitsPopulation: This parameter was analyzed in the Intent-to-Treat Population, which consisted of all subjects who were randomized and dispensed study treatment. Subjects with data available at the required visits are considered for analysis.
The ICDAS caries severity score is a parameter that reports the level of dental caries on each tooth surface using a 7-point ordinal scale ranging from 0 to 6, where higher scores are worse. When considering the time frame between two specified examinations, a clinically significant score severity score regression on a tooth surface is defined as an improvement from a score of 2 or higher to a score of 0 or 1. Tooth surfaces for which the earlier score was between 2 and 6 are defined as being at risk for caries severity regression. For each subject, the number of at-risk tooth surfaces was recorded, as well as the number of those at-risk surfaces that presented a clinically significant caries severity regression between the two examinations. For each treatment group, the mean of the subject-wise percentages of at-risk surfaces exhibiting a clinically significant caries regression was calculated.
Outcome measures
| Measure |
1.5% Arginine Dentifrice
n=389 Participants
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=393 Participants
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=409 Participants
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
0.24% Sodium Fluoride Dentifrice
n=388 Participants
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Subject-wise Tallies of Clinically Significant International Caries Detection and Assessment System (ICDAS) Caries Severity Score Regressions Between the Baseline and the Month 12 Visits
|
36.62 Percentage of tooth surfaces
Standard Deviation 30.70
|
35.01 Percentage of tooth surfaces
Standard Deviation 29.42
|
36.36 Percentage of tooth surfaces
Standard Deviation 31.02
|
36.67 Percentage of tooth surfaces
Standard Deviation 30.92
|
SECONDARY outcome
Timeframe: Between the Month 6 and the Month 12 visitsPopulation: This parameter was analyzed in the Intent-to-Treat Population, which consisted of all subjects who were randomized and dispensed study treatment. Subjects with data available at the required visits are considered for analysis.
The ICDAS caries severity score is a parameter that reports the level of dental caries on each tooth surface using a 7-point ordinal scale ranging from 0 to 6, where higher scores are worse. When considering the time frame between two specified examinations, a clinically significant score severity score regression on a tooth surface is defined as an improvement from a score of 2 or higher to a score of 0 or 1. Tooth surfaces for which the earlier score was between 2 and 6 are defined as being at risk for caries severity regression. For each subject, the number of at-risk tooth surfaces was recorded, as well as the number of those at-risk surfaces that presented a clinically significant caries severity regression between the two examinations. For each treatment group, the mean of the subject-wise percentages of at-risk surfaces exhibiting a clinically significant caries regression was calculated.
Outcome measures
| Measure |
1.5% Arginine Dentifrice
n=384 Participants
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=386 Participants
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=405 Participants
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
0.24% Sodium Fluoride Dentifrice
n=381 Participants
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Subject-wise Tallies of Clinically Significant International Caries Detection and Assessment System (ICDAS) Caries Severity Score Regressions Between the Month 6 and the Month 12 Visits
|
27.55 Percentage of tooth surfaces
Standard Deviation 29.60
|
25.61 Percentage of tooth surfaces
Standard Deviation 27.15
|
27.31 Percentage of tooth surfaces
Standard Deviation 29.93
|
28.95 Percentage of tooth surfaces
Standard Deviation 29.63
|
SECONDARY outcome
Timeframe: Between the Baseline and the Month 6 visitsPopulation: This parameter was analyzed in the Intent-to-Treat Population, which consisted of all subjects who were randomized and dispensed study treatment. Subjects with data available at the required visits are considered for analysis.
The ICDAS caries activity score is a parameter that reports the presence of active dental caries on a tooth surface utilizing a binary categorical scale of 0 (no active caries present) or 1 (active caries present). A score of 0 is the more favorable outcome. When considering the time frame between two specified examinations, a clinically significant score progression is defined as a worsening from a score of 0 to a score of 1. Surfaces with a score of 0 at the earlier examination are defined as being at risk for caries activity progression. For each subject, the number of at-risk tooth surfaces was recorded, as well as the number of those at-risk surfaces that presented a clinically significant caries activity progression between the two examinations. For each treatment group, the mean of the subject-wise percentages of at-risk surfaces exhibiting a clinically significant caries activity progression was calculated.
Outcome measures
| Measure |
1.5% Arginine Dentifrice
n=418 Participants
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=421 Participants
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=430 Participants
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
0.24% Sodium Fluoride Dentifrice
n=411 Participants
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Subject-wise Tallies of Clinically Significant International Caries Detection and Assessment System (ICDAS) Caries Activity Progressions Between the Baseline and the Month 6 Visits
|
3.71 Percentage of tooth surfaces
Standard Deviation 5.66
|
4.30 Percentage of tooth surfaces
Standard Deviation 8.20
|
3.24 Percentage of tooth surfaces
Standard Deviation 5.17
|
3.37 Percentage of tooth surfaces
Standard Deviation 5.15
|
SECONDARY outcome
Timeframe: Between the Baseline and the Month 12 visitsPopulation: This parameter was analyzed in the Intent-to-Treat Population, which consisted of all subjects who were randomized and dispensed study treatment. Subjects with data available at the required visits are considered for analysis.
The ICDAS caries activity score is a parameter that reports the presence of active dental caries on a tooth surface utilizing a binary categorical scale of 0 (no active caries present) or 1 (active caries present). A score of 0 is the more favorable outcome. When considering the time frame between two specified examinations, a clinically significant score progression is defined as a worsening from a score of 0 to a score of 1. Surfaces with a score of 0 at the earlier examination are defined as being at risk for caries activity progression. For each subject, the number of at-risk tooth surfaces was recorded, as well as the number of those at-risk surfaces that presented a clinically significant caries activity progression between the two examinations. For each treatment group, the mean of the subject-wise percentages of at-risk surfaces exhibiting a clinically significant caries activity progression was calculated.
Outcome measures
| Measure |
1.5% Arginine Dentifrice
n=389 Participants
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=393 Participants
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=409 Participants
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
0.24% Sodium Fluoride Dentifrice
n=388 Participants
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Subject-wise Tallies of Clinically Significant International Caries Detection and Assessment System (ICDAS) Caries Activity Progressions Between the Baseline and the Month 12 Visits
|
4.09 Percentage of tooth surfaces
Standard Deviation 6.28
|
4.73 Percentage of tooth surfaces
Standard Deviation 8.65
|
3.53 Percentage of tooth surfaces
Standard Deviation 5.84
|
3.37 Percentage of tooth surfaces
Standard Deviation 5.23
|
SECONDARY outcome
Timeframe: Between the Month 6 and the Month 12 visitsPopulation: This parameter was analyzed in the Intent-to-Treat Population, which consisted of all subjects who were randomized and dispensed study treatment. Subjects with data available at the required visits are considered for analysis.
The ICDAS caries activity score is a parameter that reports the presence of active dental caries on a tooth surface utilizing a binary categorical scale of 0 (no active caries present) or 1 (active caries present). A score of 0 is the more favorable outcome. When considering the time frame between two specified examinations, a clinically significant score progression is defined as a worsening from a score of 0 to a score of 1. Surfaces with a score of 0 at the earlier examination are defined as being at risk for caries activity progression. For each subject, the number of at-risk tooth surfaces was recorded, as well as the number of those at-risk surfaces that presented a clinically significant caries activity progression between the two examinations. For each treatment group, the mean of the subject-wise percentages of at-risk surfaces exhibiting a clinically significant caries activity progression was calculated.
Outcome measures
| Measure |
1.5% Arginine Dentifrice
n=389 Participants
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=392 Participants
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=409 Participants
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
0.24% Sodium Fluoride Dentifrice
n=388 Participants
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Subject-wise Tallies of Clinically Significant International Caries Detection and Assessment System (ICDAS) Caries Activity Progressions Between the Month 6 and the Month 12 Visits
|
3.23 Percentage of tooth surfaces
Standard Deviation 4.98
|
3.48 Percentage of tooth surfaces
Standard Deviation 6.29
|
2.68 Percentage of tooth surfaces
Standard Deviation 4.50
|
2.60 Percentage of tooth surfaces
Standard Deviation 4.10
|
SECONDARY outcome
Timeframe: Between the Baseline and the Month 6 visitsPopulation: This parameter was analyzed in the Intent-to-Treat Population, which consisted of all subjects who were randomized and dispensed study treatment. Subjects with data available at the required visits are considered for analysis.
The ICDAS caries activity score is a parameter that reports the presence of active dental caries on a tooth surface utilizing a binary categorical scale of 0 (no active caries present) or 1 (active caries present). A score of 0 is the more favorable outcome. When considering the time frame between two specified examinations, a clinically significant score regression is defined as an improvement from a score of 1 to a score of 0. Surfaces with a score of 1 at the earlier examination are defined as being at risk for caries activity regression. For each subject, the number of at-risk tooth surfaces was recorded, as well as the number of those at-risk surfaces that presented a clinically significant caries activity regression between the two examinations. For each treatment group, the mean of the subject-wise percentages of at-risk surfaces exhibiting a clinically significant caries activity regression was calculated.
Outcome measures
| Measure |
1.5% Arginine Dentifrice
n=418 Participants
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=421 Participants
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=430 Participants
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
0.24% Sodium Fluoride Dentifrice
n=411 Participants
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Subject-wise Tallies of Clinically Significant International Caries Detection and Assessment System (ICDAS) Caries Activity Regressions Between the Baseline and the Month 6 Visits
|
37.43 Percentage of tooth surfaces
Standard Deviation 26.30
|
38.72 Percentage of tooth surfaces
Standard Deviation 26.96
|
39.37 Percentage of tooth surfaces
Standard Deviation 27.04
|
39.43 Percentage of tooth surfaces
Standard Deviation 29.12
|
SECONDARY outcome
Timeframe: Between the Baseline and the Month 12 visitsPopulation: This parameter was analyzed in the Intent-to-Treat Population, which consisted of all subjects who were randomized and dispensed study treatment. Subjects with data available at the required visits are considered for analysis.
The ICDAS caries activity score is a parameter that reports the presence of active dental caries on a tooth surface utilizing a binary categorical scale of 0 (no active caries present) or 1 (active caries present). A score of 0 is the more favorable outcome. When considering the time frame between two specified examinations, a clinically significant score regression is defined as an improvement from a score of 1 to a score of 0. Surfaces with a score of 1 at the earlier examination are defined as being at risk for caries activity regression. For each subject, the number of at-risk tooth surfaces was recorded, as well as the number of those at-risk surfaces that presented a clinically significant caries activity regression between the two examinations. For each treatment group, the mean of the subject-wise percentages of at-risk surfaces exhibiting a clinically significant caries activity regression was calculated.
Outcome measures
| Measure |
1.5% Arginine Dentifrice
n=389 Participants
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=393 Participants
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=409 Participants
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
0.24% Sodium Fluoride Dentifrice
n=388 Participants
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Subject-wise Tallies of Clinically Significant International Caries Detection and Assessment System (ICDAS) Caries Activity Regressions Between the Baseline and the Month 12 Visits
|
54.25 Percentage of tooth surfaces
Standard Deviation 26.75
|
52.68 Percentage of tooth surfaces
Standard Deviation 26.57
|
55.40 Percentage of tooth surfaces
Standard Deviation 27.81
|
54.55 Percentage of tooth surfaces
Standard Deviation 27.79
|
SECONDARY outcome
Timeframe: Between the Month 6 and the Month 12 visitsPopulation: This parameter was analyzed in the Intent-to-Treat Population, which consisted of all subjects who were randomized and dispensed study treatment. Subjects with data available at the required visits are considered for analysis.
The ICDAS caries activity score is a parameter that reports the presence of active dental caries on a tooth surface utilizing a binary categorical scale of 0 (no active caries present) or 1 (active caries present). A score of 0 is the more favorable outcome. When considering the time frame between two specified examinations, a clinically significant score regression is defined as an improvement from a score of 1 to a score of 0. Surfaces with a score of 1 at the earlier examination are defined as being at risk for caries activity regression. For each subject, the number of at-risk tooth surfaces was recorded, as well as the number of those at-risk surfaces that presented a clinically significant caries activity regression between the two examinations. For each treatment group, the mean of the subject-wise percentages of at-risk surfaces exhibiting a clinically significant caries activity regression was calculated
Outcome measures
| Measure |
1.5% Arginine Dentifrice
n=376 Participants
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=381 Participants
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=398 Participants
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
0.24% Sodium Fluoride Dentifrice
n=371 Participants
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Subject-wise Tallies of Clinically Significant International Caries Detection and Assessment System (ICDAS) Caries Activity Regressions Between the Month 6 and the Month 12 Visits
|
40.48 Percentage of tooth surfaces
Standard Deviation 29.33
|
37.61 Percentage of tooth surfaces
Standard Deviation 27.77
|
41.23 Percentage of tooth surfaces
Standard Deviation 30.25
|
41.77 Percentage of tooth surfaces
Standard Deviation 29.23
|
Adverse Events
0.24% Sodium Fluoride Dentifrice
1.5% Arginine Dentifrice
4.0% Arginine Dentifrice
8.0% Arginine Dentifrice
Serious adverse events
| Measure |
0.24% Sodium Fluoride Dentifrice
n=500 participants at risk
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
1.5% Arginine Dentifrice
n=510 participants at risk
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=506 participants at risk
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=509 participants at risk
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Psychiatric disorders
Mental disorder
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • Number of events 1 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
Other adverse events
| Measure |
0.24% Sodium Fluoride Dentifrice
n=500 participants at risk
Toothpaste
0.24% Sodium Fluoride Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
1.5% Arginine Dentifrice
n=510 participants at risk
Toothpaste
1.5% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
4.0% Arginine Dentifrice
n=506 participants at risk
Toothpaste
4.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
8.0% Arginine Dentifrice
n=509 participants at risk
Toothpaste
8.0% Arginine Dentifrice: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
|
|---|---|---|---|---|
|
Infections and infestations
Ear infection
|
0.40%
2/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.39%
2/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Infections and infestations
Localised infection
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.39%
2/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Infections and infestations
Nasopharyngitis
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.39%
2/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Psychiatric disorders
Attention deficit hyperactivity disorder
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.39%
2/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Infections and infestations
COVID-19
|
0.40%
2/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.39%
2/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.40%
2/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.39%
2/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Aphthous ulcer
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.59%
3/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.40%
2/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
1.2%
6/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.39%
2/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Noninfective gingivitis
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.39%
2/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Oral disorder
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.59%
3/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.39%
2/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Chronic cheek biting
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Gingival bleeding
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Gingival blister
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Gingival discomfort
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Gingival erythema
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Gingival oedema
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Gingival ulceration
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Hyperaesthesia teeth
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
General disorders
Generalised oedema
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
General disorders
Inflammation
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
General disorders
Oedema
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
General disorders
Peripheral swelling
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
General disorders
Pyrexia
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Infections and infestations
Oral herpes
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Injury, poisoning and procedural complications
Accidental exposure to product
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Vascular disorders
Hypertension
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Skin and subcutaneous tissue disorders
Skin exfoliation
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Skin and subcutaneous tissue disorders
Leukoplakia
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Skin and subcutaneous tissue disorders
Blister
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Reproductive system and breast disorders
Menstruation irregular
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Psychiatric disorders
Mental disorder
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Product Issues
Device physical property issue
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Injury, poisoning and procedural complications
Upper limb fracture 0 1
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Injury, poisoning and procedural complications
Lip injury
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Injury, poisoning and procedural complications
Foot fracture
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Infections and infestations
Lyme disease
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Infections and infestations
Influenza
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Infections and infestations
Labyrinthitis
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Hepatobiliary disorders
Hepatomegaly
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Infections and infestations
Purulent discharge
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Infections and infestations
Viral infection
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Injury, poisoning and procedural complications
Ankle fracture
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Injury, poisoning and procedural complications
Eyelid injury
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Injury, poisoning and procedural complications
Ligament sprain
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Injury, poisoning and procedural complications
Mouth injury
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Injury, poisoning and procedural complications
Tooth avulsion
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Injury, poisoning and procedural complications
Tooth injury
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Metabolism and nutrition disorders
Type 2 diabetes mellitus
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion 1
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Vascular disorders
Haematoma
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Nervous system disorders
Headache
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Investigations
Weight decreased
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Injury, poisoning and procedural complications
Wrist fracture
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Injury, poisoning and procedural complications
Muscle strain
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Injury, poisoning and procedural complications
Limb injury
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Injury, poisoning and procedural complications
Concussion
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Infections and infestations
Sinusitis
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Infections and infestations
Paronychia
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Toothache
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Stomatitis
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Oral pain
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Oral discomfort
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Lip dry
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Lip swelling
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Oral cavity fistula
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Palatal ulcer
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Gastrointestinal disorders
Paraesthesia oral
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Immune system disorders
Seasonal allergy
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Infections and infestations
Gingivitis
|
0.40%
2/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Injury, poisoning and procedural complications
Hand fracture
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Injury, poisoning and procedural complications
Tooth fracture
|
0.20%
1/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Nervous system disorders
Burning sensation
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Nervous system disorders
Migraine
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Tonsillar hypertrophy
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
|
Skin and subcutaneous tissue disorders
Acne cystic
|
0.00%
0/500 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/510 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.00%
0/506 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
0.20%
1/509 • 12 months
The safety population consisted of all randomized subjects who received at least one administration of study treatment.
|
Additional Information
Domenick T. Zero (Principal Investigator)
Indiana University School of Dentistry
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place